Integral Health Asset Management’s MacroGenics MGNX Stock Holding History

Integral Health Asset Management’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-500,000	Closed	-$7.36M	–	93
2024 Q1	$7.36M	Buy	500,000 +50,000	+11%	+$756K	0.68%	57
2023 Q4	$4.33M	Buy	+450,000	New	+$3.11M	0.59%	58
2022 Q1	–	Sell	-130,000	Closed	-$2.09M	–	86
2021 Q4	$2.09M	Sell	130,000 -30,000	-19%	-$565K	0.58%	51
2021 Q3	$3.35M	Buy	+160,000	New	+$3.85M	0.96%	45
2021 Q2	–	Sell	-175,000	Closed	-$5.57M	–	84
2021 Q1	$5.57M	Buy	175,000 +85,000	+94%	+$2.06M	1.59%	24
2020 Q4	$2.06M	Hold	90,000	–	–	0.61%	45
2020 Q3	$2.27M	Buy	90,000 +20,000	+29%	+$546K	0.69%	53
2020 Q2	$1.95M	Buy	+70,000	New	+$1.22M	0.59%	53

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Integral Health Asset Management's MGNX Position: Q2 2024 in Review

Integral Health Asset Management sold out of MacroGenics (MGNX) in Q2 2024, closing a stake of 500,000 shares — an estimated $7.36M sold.

Integral Health Asset Management first reported a position in MGNX in Q2 2020 and held it in 8 quarters. The position peaked at $7.36M in Q1 2024. 146 funds tracked by Wall St. Rank hold MGNX as of Q2 2024.

Integral Health Asset Management reported no remaining MacroGenics position as of Q2 2024 after selling out during the quarter.
Integral Health Asset Management sold 500,000 MacroGenics shares in Q2 2024, an estimated $7.36M.
Integral Health Asset Management first reported a position in MacroGenics in Q2 2020 and held it in 8 quarters.
Integral Health Asset Management's MacroGenics position peaked at $7.36M in Q1 2024.
146 funds tracked by Wall St. Rank held MacroGenics as of Q2 2024.

Based on Integral Health Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.